ATE94393T1 - Dosisform zur oralen verabreichung des hypoglykaemischen glipizids. - Google Patents

Dosisform zur oralen verabreichung des hypoglykaemischen glipizids.

Info

Publication number
ATE94393T1
ATE94393T1 AT90914370T AT90914370T ATE94393T1 AT E94393 T1 ATE94393 T1 AT E94393T1 AT 90914370 T AT90914370 T AT 90914370T AT 90914370 T AT90914370 T AT 90914370T AT E94393 T1 ATE94393 T1 AT E94393T1
Authority
AT
Austria
Prior art keywords
glipicide
hypoglycaemic
oral administration
dose form
glipizide
Prior art date
Application number
AT90914370T
Other languages
English (en)
Inventor
Anthony L Kuczynski
Atul Devdatt Ayer
Patrick S-L Wong
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Application granted granted Critical
Publication of ATE94393T1 publication Critical patent/ATE94393T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Telephone Function (AREA)
  • Telephonic Communication Services (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Lubrication Of Internal Combustion Engines (AREA)
AT90914370T 1989-09-05 1990-08-31 Dosisform zur oralen verabreichung des hypoglykaemischen glipizids. ATE94393T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/402,314 US5024843A (en) 1989-09-05 1989-09-05 Oral hypoglycemic glipizide granulation
PCT/US1990/004981 WO1991003247A1 (en) 1989-09-05 1990-08-31 Dosage form for administering oral hypoglycemic glipizide

Publications (1)

Publication Number Publication Date
ATE94393T1 true ATE94393T1 (de) 1993-10-15

Family

ID=23591411

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90914370T ATE94393T1 (de) 1989-09-05 1990-08-31 Dosisform zur oralen verabreichung des hypoglykaemischen glipizids.

Country Status (20)

Country Link
US (2) US5024843A (de)
EP (1) EP0490991B1 (de)
JP (1) JP2919964B2 (de)
KR (1) KR0157640B1 (de)
AT (1) ATE94393T1 (de)
AU (1) AU632859B2 (de)
CA (1) CA2024502C (de)
DE (1) DE69003392T2 (de)
DK (1) DK0490991T3 (de)
ES (1) ES2060199T3 (de)
FI (1) FI104950B (de)
GR (1) GR1000932B (de)
HK (1) HK116897A (de)
IE (1) IE62594B1 (de)
MX (1) MX171191B (de)
NO (1) NO303963B1 (de)
NZ (1) NZ235127A (de)
PT (1) PT95169B (de)
WO (1) WO1991003247A1 (de)
ZA (1) ZA906972B (de)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591454A (en) * 1989-09-05 1997-01-07 Alza Corporation Method for lowering blood glucose
US6361795B1 (en) * 1989-09-05 2002-03-26 Alza Corporation Method for lowering blood glucose
US5024843A (en) * 1989-09-05 1991-06-18 Alza Corporation Oral hypoglycemic glipizide granulation
US5208037A (en) * 1991-04-22 1993-05-04 Alza Corporation Dosage forms comprising polymers comprising different molecular weights
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US6726930B1 (en) * 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
JP3148256B2 (ja) * 1996-07-08 2001-03-19 エドワード メンデル カンパニー．，インコーポレーテッド 高用量難溶性薬物用持続放出マトリックス
JP4863534B2 (ja) * 1996-10-25 2012-01-25 スパーナス ファーマシューティカルズ インコーポレイテッド 可溶形態浸透用量送達システム
US6361796B1 (en) * 1996-10-25 2002-03-26 Shire Laboratories, Inc. Soluble form osmotic dose delivery system
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
CN100477986C (zh) * 1996-11-25 2009-04-15 阿尔萨公司 递增剂量的剂型
ZA979605B (en) * 1996-11-25 1998-05-21 Alza Corp Ascending-dose dosage form.
EP1782798A3 (de) * 1996-11-25 2008-05-21 Alza Corporation Darreichungsform mit ansteigender Dosisfreisetzung
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US8524277B2 (en) 1998-03-06 2013-09-03 Alza Corporation Extended release dosage form
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US6099862A (en) 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
US20080213378A1 (en) * 1998-10-01 2008-09-04 Elan Pharma International, Ltd. Nanoparticulate statin formulations and novel statin combinations
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
US20040141925A1 (en) * 1998-11-12 2004-07-22 Elan Pharma International Ltd. Novel triamcinolone compositions
US6969529B2 (en) * 2000-09-21 2005-11-29 Elan Pharma International Ltd. Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
ATE391495T1 (de) * 1999-09-30 2008-04-15 Penwest Pharmaceuticals Co Matrixsystem mit verzögerter freisetzung für hochlösliche wirkstoffe
US20040156872A1 (en) * 2000-05-18 2004-08-12 Elan Pharma International Ltd. Novel nimesulide compositions
AU5459201A (en) * 2000-05-30 2001-12-11 Add Advanced Drug Delivery Technologies Ag Peroral therapeutic system comprising glipizide
AU5459301A (en) * 2000-05-30 2001-12-11 Add Advanced Drug Delivery Technologies Ag Oral delivery form comprising glipizide
US6720005B1 (en) 2000-07-07 2004-04-13 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Coated, platform-generating tablet
US7130822B1 (en) * 2000-07-31 2006-10-31 Cognos Incorporated Budget planning
US7998507B2 (en) * 2000-09-21 2011-08-16 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US20060034922A1 (en) * 2000-11-03 2006-02-16 Andrx Labs, Llc Controlled release metformin compositions
US6790459B1 (en) 2000-11-03 2004-09-14 Andrx Labs, Llc Methods for treating diabetes via administration of controlled release metformin
US6866866B1 (en) * 2000-11-03 2005-03-15 Andrx Labs, Llc Controlled release metformin compositions
CA2441064A1 (en) * 2001-03-16 2002-09-26 Andrx Corporation Controlled release sulfonylurea formulation
US6703045B2 (en) 2001-08-21 2004-03-09 Council Of Scientific & Industrial Research Composition and method for maintaining blood glucose level
BR0213079A (pt) * 2001-09-28 2004-11-09 Sun Pharmaceutical Ind Ltd Forma de dosagem para o tratamento da diabetes mellitus
US7183321B2 (en) * 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
JP4598399B2 (ja) * 2002-02-04 2010-12-15 エラン ファーマ インターナショナル，リミティド 表面安定剤としてリゾチームを有するナノ粒子組成物
US20030187074A1 (en) * 2002-03-04 2003-10-02 Javed Hussain Oral compositions for treatment of diabetes
US20030219482A1 (en) * 2002-03-21 2003-11-27 Chaudhari Sunil Sudhakar Multiparticulate compositions for once-a-day administration
US7514107B2 (en) 2002-03-21 2009-04-07 Mars, Incorporated Treatment of diseases involving defective gap junctional communication
WO2003096968A2 (en) * 2002-05-15 2003-11-27 Sun Pharmaceutical Industries Limited Oral osmotic controlled drug delivery system
WO2003099214A2 (en) * 2002-05-23 2003-12-04 Andrx Corporation Biguanide formulations
CA2492488A1 (en) * 2002-07-16 2004-01-22 Elan Pharma International, Ltd. Liquid dosage compositions of stable nanoparticulate active agents
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US20040052844A1 (en) * 2002-09-16 2004-03-18 Fang-Hsiung Hsiao Time-controlled, sustained release, pharmaceutical composition containing water-soluble resins
US20040086566A1 (en) * 2002-11-04 2004-05-06 Alpharma, Inc. Waxy matrix dosage forms
WO2004045622A1 (en) * 2002-11-15 2004-06-03 Ranbaxy Laboratories Limited Pharmaceutical dosage forms of biguanide-sulfonylurea combinations
US7611728B2 (en) * 2003-09-05 2009-11-03 Supernus Pharmaceuticals, Inc. Osmotic delivery of therapeutic compounds by solubility enhancement
JP2007509973A (ja) * 2003-10-31 2007-04-19 アルザ・コーポレーシヨン 増強された吸収のための組成物および投与形態物
WO2006046114A2 (en) * 2004-10-25 2006-05-04 Ranbaxy Laboratories Limited Osmotic dosage forms providing ascending drug release, and processes for their preparation
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
WO2007121188A2 (en) * 2006-04-10 2007-10-25 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
US8747897B2 (en) 2006-04-27 2014-06-10 Supernus Pharmaceuticals, Inc. Osmotic drug delivery system
PL2026803T3 (pl) * 2006-05-16 2012-05-31 Knopp Neurosciences Inc Kompozycje R(+) i S(-) pramipeksolu i sposoby ich zastosowania
CN100571783C (zh) * 2006-10-30 2009-12-23 北京红林制药有限公司 格列吡嗪控释片及其制备方法
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
EP2137171A4 (de) 2007-03-14 2010-05-19 Knopp Neurosciences Inc Synthese von chiralaufgereinigten substituierten benzothiazoldiaminen
US20110190356A1 (en) * 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
AU2010262970A1 (en) * 2009-06-19 2012-01-12 Knopp Neurosciences, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
CN101940578B (zh) * 2010-08-25 2012-07-25 山东新华制药股份有限公司 一种用于治疗2型糖尿病的药物组合物及其制备方法
US9512096B2 (en) 2011-12-22 2016-12-06 Knopp Biosciences, LLP Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
HRP20251187T1 (hr) 2013-07-12 2025-11-21 Areteia Therapeutics, Inc. Liječenje povišenih razina eozinofila i/ili bazofila
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
US9763918B2 (en) 2013-08-13 2017-09-19 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
US9642840B2 (en) 2013-08-13 2017-05-09 Knopp Biosciences, Llc Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders
AU2024319536A1 (en) 2023-08-08 2026-02-26 United Therapeutics Corporation A method of producing an oral osmotic pharmaceutical delivery system and a pharmaceutical batch produced using the same

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2799241A (en) * 1949-01-21 1957-07-16 Wisconsin Alumni Res Found Means for applying coatings to tablets or the like
US2909462A (en) * 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4063064A (en) * 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4016880A (en) * 1976-03-04 1977-04-12 Alza Corporation Osmotically driven active agent dispenser
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4673405A (en) * 1983-03-04 1987-06-16 Alza Corporation Osmotic system with instant drug availability
DE3320583A1 (de) * 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung
DE3320582A1 (de) * 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Gliquidonhaltige zubereitungsformen und verfahren zu ihrer herstellung
US4627851A (en) * 1984-10-26 1986-12-09 Alza Corporation Colonic-therapeutic delivery system
US4803076A (en) * 1986-09-04 1989-02-07 Pfizer Inc. Controlled release device for an active substance
MY102980A (en) * 1986-10-31 1993-03-31 Pfizer Transdermal flux enhancing compositions
US4851232A (en) * 1987-02-13 1989-07-25 Alza Corporation Drug delivery system with means for obtaining desirable in vivo release rate pattern
US4837111A (en) * 1988-03-21 1989-06-06 Alza Corporation Dosage form for dispensing drug for human therapy
US5002772A (en) * 1988-05-31 1991-03-26 Pfizer Inc. Gastric retention system for controlled drug release
US4902514A (en) * 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5028434A (en) * 1988-07-21 1991-07-02 Alza Corporation Method for administering nilvadipine for treating cardiovascular symptoms
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5019396A (en) * 1989-05-12 1991-05-28 Alza Corporation Delivery dispenser for treating cardiac arrhythmias
US5024843A (en) * 1989-09-05 1991-06-18 Alza Corporation Oral hypoglycemic glipizide granulation

Also Published As

Publication number Publication date
EP0490991B1 (de) 1993-09-15
MX171191B (es) 1993-10-06
JP2919964B2 (ja) 1999-07-19
DE69003392T2 (de) 1994-01-13
WO1991003247A1 (en) 1991-03-21
NO303963B1 (no) 1998-10-05
ZA906972B (en) 1991-06-26
NO920740L (no) 1992-02-25
PT95169A (pt) 1991-05-22
FI104950B (fi) 2000-05-15
GR900100659A (en) 1992-01-20
HK116897A (en) 1997-09-05
US5545413A (en) 1996-08-13
CA2024502A1 (en) 1991-03-06
AU632859B2 (en) 1993-01-14
KR0157640B1 (ko) 1998-11-16
EP0490991A1 (de) 1992-06-24
PT95169B (pt) 1998-06-30
IE903166A1 (en) 1991-03-13
DK0490991T3 (da) 1993-11-29
GR1000932B (el) 1993-03-16
NO920740D0 (no) 1992-02-25
KR920703066A (ko) 1992-12-17
AU6417590A (en) 1991-04-08
FI920956A0 (fi) 1992-03-04
US5024843A (en) 1991-06-18
IE62594B1 (en) 1995-02-08
ES2060199T3 (es) 1994-11-16
CA2024502C (en) 1991-03-06
DE69003392D1 (de) 1993-10-21
JPH05500222A (ja) 1993-01-21
NZ235127A (en) 1993-02-25

Similar Documents

Publication Publication Date Title
ATE94393T1 (de) Dosisform zur oralen verabreichung des hypoglykaemischen glipizids.
CA2041579A1 (en) Dosage form
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
NO306377B1 (no) Doseform for avgivelse av et medikament
AU762481C (en) Vitamin D and its analogs in the treatment of tumors and other hyperproliferative disorders
ATE96308T1 (de) Dosierform fuer verabreichung in der humanmedizin.
ATE67677T1 (de) Arzneizubereitungen zur oralen verabreichung, die als einzeldosis 10 bis 240 mg dihydropyridin enthalten.
BR9306841A (pt) Composição farmacêutica processo para proporcionar um tratamento anti-histamínico o qual não induz qualquer arritmia cardíaca significativa em um paciente ser humano e uso de uma composição para a mnaufactura de um medicamento para uso em um tratamento anti-histamínico
DK0490944T3 (da) Transmucosal doseringsform
HU883863D0 (en) Process for the preparation of producing and/or portionly form of therapeutical agents
ES2026304A6 (es) Procedimiento de fabricacion de una forma de dosificacion de nicardipina.
MY101916A (en) Etoposide oral dosage form.
GR3018365T3 (en) Use of 15-deoxyspergualine as a medicament.
RU94044812A (ru) Способ атаралгезии больных при стоматологических вмешательствах
FI930097A7 (fi) Annostusmuoto lääkeaineen antamiseksi vuorokausiterapian toteuttamista varten
SE8704081D0 (sv) A new prohylactic method
JPS6442436A (en) Rheumatoid arthritis therapeutical composition

Legal Events

Date Code Title Description
EELA Cancelled due to lapse of time